GSA Capital Partners’s Insys Therapeutics, Inc. INSY Stock Holding History

GSA Capital Partners’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-14,000	Closed	-$85K	–	2070
2018 Q1	$85K	Sell	14,000 -53,200	-79%	-$439K	﹤0.01%	1540
2017 Q4	$646K	Buy	67,200 +30,000	+81%	+$196K	0.04%	820
2017 Q3	$330K	Sell	37,200 -11,400	-23%	-$118K	0.02%	1194
2017 Q2	$615K	Sell	48,600 -32,400	-40%	-$383K	0.04%	883
2017 Q1	$851K	Buy	81,000 +34,300	+73%	+$365K	0.05%	749
2016 Q4	$430K	Sell	46,700 -46,200	-50%	-$522K	0.03%	1102
2016 Q3	$1.09M	Buy	+92,900	New	+$1.41M	0.06%	563
2016 Q2	–	Sell	-94,878	Closed	-$1.52M	–	2000
2016 Q1	$1.52M	Sell	94,878 -131,834	-58%	-$2.5M	0.1%	313
2015 Q4	$6.49M	Buy	226,712 +199,252	+726%	+$5.52M	0.32%	12
2015 Q3	$782K	Sell	27,460 -2,000	-7%	-$73.6K	0.04%	837
2015 Q2	$1.06M	Sell	29,460 -110	-0.4%	-$3.43K	0.04%	839
2015 Q1	$859K	Buy	+29,570	New	+$782K	0.03%	989

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

GSA Capital Partners's INSY Position: Q2 2018 in Review

GSA Capital Partners sold out of Insys Therapeutics, Inc. (INSY) in Q2 2018, closing a stake of 14,000 shares — an estimated $85K sold.

GSA Capital Partners first reported a position in INSY in Q1 2015 and held it in 12 quarters. The position peaked at $6.49M in Q4 2015. 103 funds tracked by Wall St. Rank hold INSY as of Q2 2018.

GSA Capital Partners reported no remaining Insys Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
GSA Capital Partners sold 14,000 Insys Therapeutics, Inc. shares in Q2 2018, an estimated $85K.
GSA Capital Partners first reported a position in Insys Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
GSA Capital Partners's Insys Therapeutics, Inc. position peaked at $6.49M in Q4 2015.
103 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2018.

Based on GSA Capital Partners's 13F filing for Q2 2018, filed 9 Aug 2018.